Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients
Sirolimus lowers skin cancer risk in kidney transplant patients
This meta-analysis of four randomized trials in kidney transplant recipients with prior cutaneous squamous cell carcinoma found that switchi…
A review of studies shows switching to sirolimus can cut skin cancer rates, but it may cause more side effects.